ABT
Abbott Laboratories
102.60$
+0.4%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +0.8% | +2.2% | +31.3% | +11.6% | +4.3% | +8.5% | +24.5% | +1.3% | -8.1% | +4.6% | +5.7% | |
| – | -3.2% | +1.7% | +49.1% | +3.0% | +3.1% | +13.3% | +15.3% | +7.4% | -5.9% | +2.8% | -4.4% | |
| – | +4.5% | +2.6% | +16.2% | +21.1% | +5.5% | +4.1% | +33.6% | -3.8% | -10.2% | +6.4% | +15.4% | |
| – | +6.5% | -0.8% | +56.8% | +7.4% | +5.2% | +0.4% | +13.2% | +4.2% | -4.7% | +3.8% | +4.7% | |
| – | +3.9% | -1.7% | +36.6% | +6.9% | +0.2% | -0.7% | +16.8% | -2.8% | +1.7% | +4.5% | +5.8% | |
| – | +5.8% | -0.2% | +38.8% | +8.0% | +1.0% | -0.1% | +16.0% | -0.4% | -2.6% | +6.4% | +14.6% | |
| – | +1.1% | +10.2% | -39.3% | +94.9% | +19.4% | +15.2% | +73.9% | -9.1% | -23.0% | +6.1% | +17.9% | |
| – | +8.5% | +70.8% | +189.5% | -17.2% | +12.2% | -13.4% | -42.1% | -23.2% | +121.6% | -13.6% | -43.4% | |
| – | +26.4% | -55.6% | +57.9% | +28.8% | +41.9% | +21.9% | +65.3% | +1.2% | -19.8% | +5.2% | +20.7% | |
| – | -27.6% | -39.3% | +436.6% | -71.3% | -27.6% | +27.4% | +129.4% | +20.4% | -31.5% | -779.0% | – | |
| – | +93.7% | -68.3% | -65.9% | +396.4% | +55.7% | +21.9% | +57.3% | -2.0% | -17.5% | +134.2% | -51.3% | |
| – | +16.3% | -36.5% | +99.7% | +12.2% | +15.0% | +13.8% | +35.1% | -2.2% | -10.8% | +2.2% | +6.6% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.